We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

REP1 Gene Replacement Therapy for Choroideremia (REGENERATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02407678
Recruitment Status : Completed
First Posted : April 3, 2015
Last Update Posted : August 5, 2021
Sponsor:
Collaborators:
Moorfields Eye Hospital NHS Foundation Trust
University College, London
Information provided by (Responsible Party):
University of Oxford

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The assessment of the efficacy (with respect to preservation of visual function and retinal structure) and safety of a single subretinal injection of AAV2.REP1 in participants with a confirmed diagnosis of choroideremia, as evaluated by various functional and anatomical outcomes measured over a number of time points up to 24 months post-treatment.

Condition or disease Intervention/treatment Phase
Choroideremia Genetic: AAV-mediated REP1 gene replacement Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The decision about which eye to treat will be made on clinical grounds and will generally be the worse eye affected in cases where BCVA differs between the two eyes by 2 lines or more of ETDRS letters. The eye to be treated will be randomised in cases where the degeneration is relatively symmetrical between the two eyes, defined as:

  • a difference in BCVA of no more than 1 line of ETDRS letters, and
  • no more than 25% difference in the area of surviving RPE as measured by fundus autofluorescence.

Prospective participants having non-symmetrical retinal degeneration will be allocated to the non-randomised arm. The treated eye will generally be the worse eye. Prospective participants having relatively symmetrical retinal degeneration will be allocated to the randomised arm.
Masking: None (Open Label)
Masking Description: The study is designated as Open Label with no masking. However, in order to minimise bias evaluation of the treated eye and untreated fellow eye (control eye), the ophthalmic assessments (visual acuity, microperimetry, fundus autofluorescence, etc.) will be conducted by an appropriately qualified masked observer once the participant's treated eye has had time to heal after the surgical procedure and has regained its normal appearance and function.
Primary Purpose: Treatment
Official Title: An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Actual Study Start Date : August 16, 2016
Actual Primary Completion Date : July 23, 2021
Actual Study Completion Date : July 23, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment
Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
 Genetic: AAV-mediated REP1 gene replacement
AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
No Intervention: Control
Untreated eye


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from baseline in best corrected visual acuity in the treated eye [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Change from baseline in the central visual field in the treated eye as determined by microperimetry [ Time Frame: 2 years ]
  2. Change from baseline in the area of surviving retinal pigment epithelium in the treated eye as measured by fundus autofluorescence, compared to the untreated fellow eye (control eye) after randomisation of treatment to one eye or the other [ Time Frame: 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Candidate is willing and able to give informed consent for participation in the study.
  2. Male aged 18 years or above.
  3. Genetic or molecular confirmed diagnosis of choroideremia (REP1 protein deficiency).
  4. Active disease visible clinically within the macula region.
  5. Best corrected visual acuity better than or equal to 6/60 (20/200; Decimal 0.1; LogMAR 1.0) in the study eye.

Exclusion Criteria:

  1. Any female, or a male aged below 18 years.
  2. An additional cause for sight loss (e.g. amblyopia) in the eye to be treated.
  3. Any other significant ocular and non-ocular disease or disorder which, in the opinion of the investigator, may put the participants at risk because of participation in the study.
  4. Inability to take systemic prednisolone for a period of 45 days.
  5. Unwillingness to use barrier contraception methods for a period of three months following gene therapy surgery.
  6. Participation in another research study involving an investigational product in the preceding 12 weeks.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02407678


Locations
Layout table for location information
United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom, EC1V 2PD
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
University of Oxford
Moorfields Eye Hospital NHS Foundation Trust
University College, London
Investigators
Layout table for investigator information
Principal Investigator: Robert E MacLaren, MB ChB DPhil University of Oxford
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT02407678    
Other Study ID Numbers: REGEN2015
First Posted: April 3, 2015    Key Record Dates
Last Update Posted: August 5, 2021
Last Verified: July 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Choroideremia
Eye Diseases, Hereditary
Eye Diseases
Choroid Diseases
 Uveal Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked